Aravax Begins Phase 2 Trial of Peanut Allergy Candidate miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
MELBOURNE, Australia, June 1, 2023 /PRNewswire/ The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application. Allergy clinical trial centres across Victoria, South Australia, New South Wales, and Western Australia have invited children and adolescents aged four to 17 years with peanut allergy to take part in the Phase 2 study. Researchers aim to evaluate the efficacy of the novel therapy PVX108. In Phase 1 trials, researchers observed that PVX108 produced relevant changes in the immune response to peanut protein, which continued to develop once dosing had completed. "We're thrilled to have dosed our first patient in Phase 2. In this Phase 2 trial we will evaluate how the immunological changes observed in Phase 1 trials translate to clinical reductions
Aravax doses first patient in Phase 2 peanut allergy clinical trials fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
The family and friends of 15-year-old Max McKenzie, who suffered a fatal anaphylactic reaction when he ate an apple pie he didn t realise contained nuts, are banding together to help others.
According to a new study, a simple nasal spray significantly reduced snoring and breathing difficulties in children and halved the number needing to have their tonsils removed.